Ratliff John D
Insider transactions at 2 companies
This page shows all SEC Form 4 filings attributed to Ratliff John D. Form 4 disclosures are required whenever a corporate insider — director, officer, or 10%+ shareholder — buys, sells, or receives company stock. Each row represents a separate reported transaction. All data is sourced directly from the SEC EDGAR public database.
| Company | Title | Type | Shares | Price | Value | Date |
|---|---|---|---|---|---|---|
| LH | CEO, Covance Drug Development | Option Exercise | 2,424 | — | — | Apr 3, 2019 |
| LH | CEO, Covance Drug Development | Option Exercise | 1,463 | — | — | Feb 12, 2019 |
| LH | CEO, Covance Drug Development | Tax Withholding | 1,973 | $144.29 | $284,684 | Feb 11, 2019 |
| LH | CEO, Covance Drug Development | Tax Withholding | 556 | $147.46 | $81,988 | Feb 7, 2019 |
| LH | CEO, Covance Drug Development | Tax Withholding | 2,132 | $168.08 | $358,347 | Feb 9, 2018 |
| LH | CEO, Covance Drug Development | Tax Withholding | 560 | $169.66 | $95,010 | Feb 7, 2018 |
| LH | CEO, Covance Drug Development | Option Exercise | 6,100 | — | — | Feb 9, 2017 |
| IQV | President and COO | Sale | 115,000 | $42.55 | $4,893,250 | Nov 18, 2013 |